Cambridge Trust Co. Has $18.39 Million Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Cambridge Trust Co. decreased its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 19.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 358,307 shares of the biopharmaceutical company’s stock after selling 84,966 shares during the quarter. Cambridge Trust Co.’s holdings in Bristol-Myers Squibb were worth $18,385,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of BMY. Twin Capital Management Inc. raised its stake in shares of Bristol-Myers Squibb by 13.4% during the fourth quarter. Twin Capital Management Inc. now owns 83,162 shares of the biopharmaceutical company’s stock worth $4,267,000 after buying an additional 9,831 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt lifted its position in shares of Bristol-Myers Squibb by 1.9% in the fourth quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 107,068 shares of the biopharmaceutical company’s stock worth $5,490,000 after purchasing an additional 1,962 shares in the last quarter. Daiwa Securities Group Inc. boosted its stake in shares of Bristol-Myers Squibb by 6.8% during the 4th quarter. Daiwa Securities Group Inc. now owns 190,525 shares of the biopharmaceutical company’s stock worth $9,776,000 after acquiring an additional 12,160 shares during the period. KLCM Advisors Inc. raised its position in shares of Bristol-Myers Squibb by 24.4% in the fourth quarter. KLCM Advisors Inc. now owns 390,691 shares of the biopharmaceutical company’s stock valued at $20,046,000 after buying an additional 76,740 shares in the last quarter. Finally, Rakuten Securities Inc. acquired a new stake in Bristol-Myers Squibb during the fourth quarter worth approximately $44,000. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Performance

Shares of Bristol-Myers Squibb stock traded up $0.21 on Thursday, reaching $48.05. 5,919,010 shares of the company traded hands, compared to its average volume of 15,712,627. The company has a 50 day moving average of $51.26 and a 200 day moving average of $51.59. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.43 and a quick ratio of 1.31. Bristol-Myers Squibb has a 52 week low of $47.58 and a 52 week high of $70.93. The firm has a market capitalization of $97.39 billion, a PE ratio of 12.46, a PEG ratio of 1.49 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.55 by $0.15. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. The firm had revenue of $11.48 billion for the quarter, compared to analyst estimates of $11.19 billion. During the same period in the previous year, the company posted $1.82 earnings per share. The business’s revenue was up .6% on a year-over-year basis. Equities analysts forecast that Bristol-Myers Squibb will post 6.47 earnings per share for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be given a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 4.99%. The ex-dividend date of this dividend is Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 62.18%.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Societe Generale downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. Wells Fargo & Company increased their target price on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a report on Thursday. William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. StockNews.com cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Monday. Finally, Bank of America cut Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $68.00 to $60.00 in a report on Wednesday, January 3rd. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $61.18.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.